https://www.thedailybeast.com/fda-keeps-brand-name-drugs-on-a-fast-path-to-market-despite-manufacturing-concerns
Wednesday, November 6, 2019
FDA Keeps Brand-Name Drugs On A Fast Path To Market ― Despite Manufacturing Concerns
The agency approved Gilead’s “game changer” hepatitis C cure, bypassing concerns raised by its own federal inspectors.
https://www.thedailybeast.com/fda-keeps-brand-name-drugs-on-a-fast-path-to-market-despite-manufacturing-concerns
https://www.thedailybeast.com/fda-keeps-brand-name-drugs-on-a-fast-path-to-market-despite-manufacturing-concerns
Subscribe to:
Post Comments (Atom)
Click Older Posts above to see more.
No comments:
Post a Comment